Linearis Ventures and Other Funds Invest in Noetik’s Oversubscribed Series A $40M USD Accelerating AI-Drug Development Platform for Precision Cancer Therapies

August 29, 2024 16:00 Eastern Daylight Time

Quebec City, Canada- Linearis Ventures, a life science VC fund focusing on AI-enabling healthcare, is thrilled to confirm its investment in Noetik’s oversubscribed $40M USD Series A financing round. Noetik is an AI-native biotech company leveraging self-supervised machine learning and high-throughput spatial proprietary data to develop next-generation cancer therapeutics. 

The financing was led by Polaris Partners with participation from new investors Khosla Ventures, Wittington Ventures and Breakout Ventures. The round was supported by all existing investors DCVC, Zetta Venture Partners, Catalio Capital Management, 11.2 Capital, Epic Ventures, Intermountain Ventures and North South Ventures. The round also included AI funds ApSTAT Technologies, Linearis Ventures, supported by leading AI expert Yoshua Bengio and metabolomic expert David Wishart, Element AI co-founder Jean-François Gagné, and current and former Recursion executives.

Funds from the Series A financing will be used to expand Noetik’s spatial omics-based atlas of human cancer biology (already one of the world’s largest) together with its high throughput in vivo CRISPR Perturb-Map platform. Additionally, the investment will enable the company to scale training of its multi-modal cancer foundation models such as OCTO. 

“Linearis Ventures is excited to be amongst other visionary investors who have supported several breakthrough technologies to take part in Noetik’s Series A to further accelerate the company’s growth and innovations in the development of precision oncology therapeutics” said Alexandre Le Bouthillier PhD, Linearis Ventures- General Partner.

About Linearis 

Linearis with its tandem Ventures Fund and Laboratory is pioneering and supporting discoveries to prevent, detect, and cure metabolic diseases including cancers & diabetes through direct investments in innovative AI-powered life sciences companies.

To learn more about Linearis Ventures visit us at: https://www.linearis.com/

Linearis- Media Contact: 

Manon Boisclair MS, MBA, ICD.D, General Partner (media@linearis.com) 

Cautionary statement regarding forward-looking statements

Linearis cautions investors that any forward-looking statements made by Linearis, including those made in this announcement such as business objectives and other statements that are not historical facts, are subject to inherent risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include but are not limited to, those described in Linearis’ Financial Report and changes in market conditions, customer demand, competition, regulatory issues, and other unforeseen events. You are cautioned not to place undue reliance on forward-looking statements, which reflect projections only as of the date of this press release. Except as may be required by applicable law, Linearis disclaims any intention or obligation to update or revise any forward-looking statements.